Zobrazeno 1 - 10
of 126
pro vyhledávání: '"R. Gralla"'
Autor:
R. Gralla, Claire E Higham, Florian Scotté, Tim Cooksley, E. Darlington, Richard Berman, Andrew Davies, L. Carter
Publikováno v:
Clinical Oncology (Royal College of Radiologists (Great Britain)
Clinical Oncology
Clinical Oncology
The advent of new cancer therapies, alongside expected growth and ageing of the population, better survival rates and associated costs of care, is uncovering a need to more clearly define and integrate supportive care services across the whole spectr
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Intermetallics. 47:6-10
An attempt has been made to develop a new metallic glass (MG) that combines high hardness with wear resistance. Refractory metallic films of W33Ni32B35 (at.%) have been deposited on stainless steel and Si substrates by dc magnetron sputtering. The al
Publikováno v:
Annals of Oncology. 27
Autor:
R. Gralla
Publikováno v:
Journal of Thoracic Oncology. 13:S287-S288
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Composite Materials. 47:2087-2096
In this study, polyetheretherketone composites were compounded using a two-screw extruder followed by injection moulding. The effects of multi-fillers on the mechanical properties and crystallization performances were investigated. Differential scann
Autor:
R. Gralla
Publikováno v:
Journal of Thoracic Oncology. 12:S1640
Publikováno v:
Annals of Oncology. 10:S47-S51
The investigation of the activity of vinorelbine in non-small-cell lung cancer (NSCLC) has continued beyond the initial studies which established its single agent activity and defined the combination of vinorelbine and cisplatin as one of the standar
Publikováno v:
Annals of Oncology. 10:S41-S45
Initial studies of vinorelbine (Navelbine®) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30% could be obtained with a schedule of 30 mg/m 2 given weekly. Alth